Ranbaxy settles patent dispute

0
552
dispute between AstraZeneca and India’s Ranbaxy
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

Anglo-Swedish pharmaceutical company AstraZeneca and India’s Ranbaxy have settled a legal dispute over the hugely profitable ulcer drug Nexium.

The agreement brings to an end a case that began in 2005 when AstraZeneca sued Ranbaxy in a federal court in New Jersey after Ranbaxy requested US Food and Drug Administration approval to sell its generic version of Nexium.

AstraZeneca alleged that Ranbaxy was violating patents on the drug, which is known generically as esomeprazole.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link